艾司西酞普兰治疗围绝经期抑郁对照观察

Comparative observation on patients with perimenopausal depression treated by escitalopram

目的:观察艾司西酞普兰联合激素对围绝经期中重度抑郁症的临床疗效。方法:50例围绝经期中重度抑郁症患者随机分为合用组和单用组。合用组给予艾司西酞普兰和替勃龙,单用组给予替勃龙,用Montgomery and Asberg抑郁量表(MADRS)和Kupperman绝经指数(KMI)对患者进行治疗8周观察。结果:完成研究43例,其中合用组22例,单用组21例。合用组有效率90.9%,对照组有效率71.4%。合用组治疗1周后MADRS评分与治疗前差异有显著性,而单用组到第2周与治疗前有差异。治疗第2周时,两组之间MADRS评分差异有显著性,这种差异一直持续到8周末。在KMI改善方面,两组在治疗第1周均比治疗前有显著改善,到第2周时,合用组与单用组间KMI评分差异有显著性,这种差异一直持续到8周末。结论:艾司西酞普兰联用雌激素能够在治疗1周内显著改善患者抑郁症状和KMI,并且能够持续改善患者的症状,这种疗效优于单用雌激素治疗。

Objective： To compare curative effects between hormone replacement therapy （HRT）alone and HRT plus eseitalopram on the patients with perimenopausal depression. Method：50 patients were randomly divided into the combined therapy group with tibolon plus escitalopram and the single therapy group treated with tibolon only. The degrees of depression and perimenopausal symptoms were assessed with Montgomery and Asberg depression rating scale（MADRS） and Kupperman mark index（KMI） respectively. Results：Clinical curative rates at the end of this study were respectively 90.9% in study group and 71.4% in control group. There were not significant differences between the two groups in MADS and KMI at baseline, but at the end of the study. Conclusion： HRT plus escitalopram might have satisfactory effectiveness than HRT alone in the treatment of perimenopausal depression.